menu search

Galapagos shares down after announcing clinical-trial miss for crohn's disease

U.S.-listed shares of Galapagos GLPG, +0.41% were down 8.9% in premarket trading on Thursday, the day after the company said an experimental treatment...

February 9, 2023, 8:35 am

Celadrin supplements market sees significant increase in demand at a cagr 7.3% by 2033 | persistence market research

Increase in Demand of Celadrin Supplements for arthritis Patients to pave way for Celadrin Supplements ...

February 8, 2023, 2:05 pm

Adding multimedia mymd pharmaceuticals® to present data on oral tnf-a inhibitor mymd-1® at the british society for immunology (bsi) congress 2022

BALTIMORE--( BUSINESS WIRE )--MyMD Pharmaceuticals, Inc. ® (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage biopharmaceutical compa...

December 6, 2022, 9:40 am

Sorrento to host webcast to discuss newly presented clinical data demonstrating significant improvements in therapeutic outcomes in 10 of 10 patients with poorly controlled rheumatoid arthritis

ATLANTA and SAN DIEGO, Nov. 13, 2022 (GLOBE NEWSWIRE) — Sofusa®, a wholly-owned division of Sorrento Therapeutics (Nasdaq: SRNE, “Sorrento”), t...

November 13, 2022, 8:02 pm

Sorrento to host webcast to discuss newly presented clinical data demonstrating significant improvements in therapeutic outcomes in 10 of 10 patients with poorly controlled rheumatoid arthritis

ATLANTA and SAN DIEGO, Nov. 13, 2022 (GLOBE NEWSWIRE) -- Sofusa®, a wholly-owned division of Sorrento Therapeutics (Nasdaq: SRNE, “Sorrento”), to...

November 13, 2022, 3:02 pm

Wellbeing digital sciences says kgk science subsidiary announces positive results from study on gj 191 supplement for osteoarthritis

Wellbeing Digital Sciences (NEO:MEDI.AQN, OTCQB:KONEF) Inc announced that a clinical study conducted by its wholly-owned subsidiary, KGK Science Inc, ...

June 16, 2022, 8:08 am

Abbvie misses quarterly sales estimates as humira rivals bite

AbbVie Inc missed Wall Street estimates for first-quarter sales on Friday, hurt by European competition for its blockbuster rheumatoid ...

April 29, 2022, 7:49 am

Ampio pharma shares fall as fda rejects proposed change in knee osteoarthritis trial

Ampio Pharmaceuticals Inc (NYSE: AMPE) received written responses from the FDA pursuant to a Type C meeting request regarding the AP-013 Phase 3 tria...

April 21, 2022, 6:29 am

Roche (rhhby) actemra application receives priority review

Roche (RHHBY) sBLA is seeking approval for the intravenous formulation of arthritis drug Actemra accept...

April 5, 2022, 1:33 pm

Vyne therapeutics shares jump on encouraging preclinical data from vyn201 program in rheumatoid arthritis

VYNE Therapeutics Inc (NASDAQ: VYNE) announced positive preclinical data from its VYN201 program in the rheumatoid ...

March 30, 2022, 11:43 am

Abbvie snags fda approval for another indication. will it become another blockbuster?

Immunology drug Skyrizi was authorized by the Food and Drug Administration to treat psoriatic arthritis...

February 18, 2022, 8:38 am

Abbvie snags fda approval for another indication. will it become another blockbuster?

Immunology drug Skyrizi was authorized by the Food and Drug Administration to treat psoriatic arthritis...

February 18, 2022, 8:38 am

Abbvie snags fda approval for another indication. will it become another blockbuster?

Immunology drug Skyrizi was authorized by the Food and Drug Administration to treat psoriatic arthritis...

February 18, 2022, 8:38 am

Biogen (biib) inks agreement to add new biosimilar candidate

Biogen (BIIB) signs an agreement with Xbrane Biopharma for exclusive global rights to the latter's biosimilar candidate, Xcimzane, referencing UCB's <...

February 8, 2022, 1:04 pm

Biogen (biib) inks agreement to add new biosimilar candidate

Biogen (BIIB) signs an agreement with Xbrane Biopharma for exclusive global rights to the latter's biosimilar candidate, Xcimzane, referencing UCB's <...

February 8, 2022, 1:04 pm

Biogen (biib) inks agreement to add new biosimilar candidate

Biogen (BIIB) signs an agreement with Xbrane Biopharma for exclusive global rights to the latter's biosimilar candidate, Xcimzane, referencing UCB's <...

February 8, 2022, 1:04 pm

Enveric biosciences advancing clinical plans as it announces two new molecules to treat osteoarthritis and other pain conditions

Enveric Biosciences (NASDAQ:ENVB) said that two new molecules, EV104a and EV104b, have been created to treat osteo...

February 8, 2022, 8:55 am

Enveric biosciences advancing clinical plans as it announces two new molecules to treat osteoarthritis and other pain conditions

Enveric Biosciences (NASDAQ:ENVB) said that two new molecules, EV104a and EV104b, have been created to treat osteo...

February 8, 2022, 8:55 am

Enveric biosciences advancing clinical plans as it announces two new molecules to treat osteoarthritis and other pain conditions

Enveric Biosciences (NASDAQ:ENVB) said that two new molecules, EV104a and EV104b, have been created to treat osteo...

February 8, 2022, 8:55 am


Search within

Pages Search Results: